271 related articles for article (PubMed ID: 29728092)
1. Cytoreductive treatment patterns among US veterans with polycythemia vera.
Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
BMC Cancer; 2018 May; 18(1):528. PubMed ID: 29728092
[TBL] [Abstract][Full Text] [Related]
2. Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.
Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
Ann Hematol; 2019 Nov; 98(11):2533-2539. PubMed ID: 31552445
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Mancuso S; Santoro M; Accurso V; Agliastro G; Raso S; Di Piazza F; Perez A; Bono M; Russo A; Siragusa S
Oncol Res Treat; 2020; 43(10):526-530. PubMed ID: 32772025
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
Jentsch-Ullrich K; Eberhardt J; Zeremski V; Koehler M; Wolleschak D; Heidel FH
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2041-9. PubMed ID: 27431664
[TBL] [Abstract][Full Text] [Related]
6. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
7. Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data.
Paranagama D; Colucci P; Evans KA; Bonafede M; Parasuraman S
Exp Hematol Oncol; 2018; 7():16. PubMed ID: 30002948
[TBL] [Abstract][Full Text] [Related]
8. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
10. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
11. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Parasuraman SV; Shi N; Paranagama DC; Bonafede M
J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
[TBL] [Abstract][Full Text] [Related]
12. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
Ann Intern Med; 1995 Nov; 123(9):656-64. PubMed ID: 7574220
[TBL] [Abstract][Full Text] [Related]
14. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns.
Streiff MB; Smith B; Spivak JL
Blood; 2002 Feb; 99(4):1144-9. PubMed ID: 11830459
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis.
Gumina RJ; Foley DA; Tefferi A; Rooke TW; Shields RC
Angiology; 2002; 53(5):587-91. PubMed ID: 12365868
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Grunwald MR; Stein BL; Boccia RV; Oh ST; Paranagama D; Parasuraman S; Colucci P; Mesa R
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):788-795.e2. PubMed ID: 30245100
[TBL] [Abstract][Full Text] [Related]
17. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
18. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.
Podoltsev NA; Zhu M; Zeidan AM; Wang R; Wang X; Davidoff AJ; Huntington SF; Giri S; Gore SD; Ma X
Blood Adv; 2018 Oct; 2(20):2681-2690. PubMed ID: 30333100
[TBL] [Abstract][Full Text] [Related]
19. Elevated White Blood Cell Levels and Thrombotic Events in Patients With Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data.
Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):63-69. PubMed ID: 31865003
[TBL] [Abstract][Full Text] [Related]
20. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
